Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Hideki Onimatsu"'
Autor:
Toshiyoshi Fujiwara, Yasuo Urata, Hideki Onimatsu, Yuuri Hashimoto, Yuichi Watanabe, Shinji Kuroda, Masaaki Ouchi, Toru Kojima, Dong Liu
Supplementary Fig. S1 from Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1db95c45ddcfe9f6b72abbaa972dc7ef
https://doi.org/10.1158/1535-7163.22485089
https://doi.org/10.1158/1535-7163.22485089
Autor:
Toshiyoshi Fujiwara, Satoru Shintani, Yasuo Urata, Hiroyuki Mizuguchi, Satoru Kyo, Dong Liu, Masashi Hatori, Tatsuo Shirota, Toru Kojima, Hideki Onimatsu, Yuichi Watanabe, Yuji Kurihara
Purpose: Long-term outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) remain unsatisfactory despite advances in combination of treatment modalities. SCCHN is characterized by locoregional spread and it is clinically access
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76268a1faf0fe580cda5dc9420a99d81
https://doi.org/10.1158/1078-0432.c.6517671.v1
https://doi.org/10.1158/1078-0432.c.6517671.v1
Autor:
Toshiyoshi Fujiwara, Yasuo Urata, Hideki Onimatsu, Yuuri Hashimoto, Yuichi Watanabe, Shinji Kuroda, Masaaki Ouchi, Toru Kojima, Dong Liu
A phase I dose-escalation study of telomerase-specific oncolytic adenovirus, OBP-301 (Telomelysin), is now under way in the United States to assess feasibility and to characterize its pharmacokinetics in patients with advanced solid tumors. The prese
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bf39532e5d46a00157b7498ccf0fba2
https://doi.org/10.1158/1535-7163.c.6531764
https://doi.org/10.1158/1535-7163.c.6531764
Autor:
Toshiyoshi Fujiwara, Yasuo Urata, Hideki Onimatsu, Yuuri Hashimoto, Yuichi Watanabe, Shinji Kuroda, Masaaki Ouchi, Toru Kojima, Dong Liu
Supplementary Fig. S3 from Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97a3995b2de59b310a9e546bc1f81ab4
https://doi.org/10.1158/1535-7163.22485083
https://doi.org/10.1158/1535-7163.22485083
Autor:
Toshiyoshi Fujiwara, Satoru Shintani, Yasuo Urata, Hiroyuki Mizuguchi, Satoru Kyo, Dong Liu, Masashi Hatori, Tatsuo Shirota, Toru Kojima, Hideki Onimatsu, Yuichi Watanabe, Yuji Kurihara
Supplementary Data from Telomerase-Specific Virotheranostics for Human Head and Neck Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d116898347359d6cb2c9a4ff1180bc4
https://doi.org/10.1158/1078-0432.22440324.v1
https://doi.org/10.1158/1078-0432.22440324.v1
Autor:
Toshiyoshi Fujiwara, Yasuo Urata, Hideki Onimatsu, Yuuri Hashimoto, Yuichi Watanabe, Shinji Kuroda, Masaaki Ouchi, Toru Kojima, Dong Liu
Supplementary Fig. S4 from Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fe4daec5b3065732781536a50376c1b
https://doi.org/10.1158/1535-7163.22485077.v1
https://doi.org/10.1158/1535-7163.22485077.v1
Autor:
Toshiyoshi Fujiwara, Yasuo Urata, Hideki Onimatsu, Yuuri Hashimoto, Yuichi Watanabe, Shinji Kuroda, Masaaki Ouchi, Toru Kojima, Dong Liu
Supplementary Fig. S2 from Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03e4c98e2cbdcd3f4c669a81588ff6fe
https://doi.org/10.1158/1535-7163.22485086
https://doi.org/10.1158/1535-7163.22485086
Autor:
Hiroyuki Mizuguchi, Hideki Onimatsu, Yasuo Urata, Toshiyoshi Fujiwara, Yuji Kurihara, Satoru Kyo, Masashi Hatori, Toru Kojima, Satoru Shintani, Dong Liu, Tatsuo Shirota, Yuichi Watanabe
Publikováno v:
Clinical Cancer Research. 15:2335-2343
Purpose: Long-term outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) remain unsatisfactory despite advances in combination of treatment modalities. SCCHN is characterized by locoregional spread and it is clinically access
Autor:
Hideki Onimatsu, Masaaki Ouchi, Toru Kojima, Dong Liu, Shinji Kuroda, Yasuo Urata, Yuuri Hashimoto, Toshiyoshi Fujiwara, Yuichi Watanabe
Publikováno v:
Molecular Cancer Therapeutics. 8:980-987
A phase I dose-escalation study of telomerase-specific oncolytic adenovirus, OBP-301 (Telomelysin), is now under way in the United States to assess feasibility and to characterize its pharmacokinetics in patients with advanced solid tumors. The prese
Autor:
Yasuo Urata, Yuichi Watanabe, Hideki Onimatsu, Noriaki Tanaka, Yoshikatsu Endo, Ryo Sakai, Futoshi Uno, Toshiyoshi Fujiwara, Masayoshi Hioki, Shunsuke Kagawa, Masaaki Ouchi
Publikováno v:
Oncogene. 27:2375-2381
Dendritic cells (DCs) are the most potent antigen-presenting cells and acquire cellular antigens and danger signals from dying cells to initiate antitumor immune responses via direct cell-to-cell interaction and cytokine production. The optimal forms